FDA Clears sCAR-T Therapy IND for Autoimmune Disease Treatment
β’ FDA has approved an investigational new drug application for synthetic CAR-T (sCAR-T) therapy targeting autoimmune conditions. β’ The clearance enables clinical trials to test this engineered cell therapy in US patients with refractory autoimmune diseases. β’ sCAR-T represents a novel approach adapting cancer immunotherapy for immune disorders, potentially offering durable remissions.
Read original Β· news-medical.net
